Expert Opinion on Drug Metabolism & Toxicology

Article	Citations
The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury	107
Pharmacokinetic evaluation of bictegravir + emtricitabine + tenofovir alafenamide in HIV treatment	98
The impact of genetic variability on Alzheimer’s therapies: obstacles for pharmacogenetic progress	65
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects	57
Preventable serious drug-disease interactions of reserve antibiotics	55
Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations	49
Population toxicokinetics of carbamazepine and its metabolite carbamazepine-10,11-epoxide in adults	44
Review and evaluation of vancomycin dosing guidelines for obese individuals	35
Biomarkers of 4-hydroxy-N,N-methylpropyltryptamine (4-OH-MPT) intake identified from human hepatocyte incubations	32
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies	31
A pharmacokinetic evaluation of tenapanor for the treatment of irritable bowel syndrome with constipation: an update of the literature	29
Drug-drug interactions between COVID-19 drug therapies and antidepressants	27
Combined oral contraceptive with estetrol plus drospirenone: from pharmacokinetics to clinical applications	25
A systematic review on the clinical pharmacokinetics of vildagliptin in healthy and disease populations	24
Induction effect of antiretroviral bictegravir on the expression of Abcb1, Abcg2 and Abcc1 genes associated with P-gp, BCRP and MRP1 transporters present in rat peripheral blood mononuclear cells	21
Predicting the pharmacokinetics and pharmacodynamics of antisense oligonucleotides: an overview of various approaches and opportunities for PBPK/PD modelling	21
An update on microfluidic multi-organ-on-a-chip systems for reproducing drug pharmacokinetics: the current state-of-the-art	20
Comorbidities and the right dose: antipsychotics	18
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update	18
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine	18
The impact ofcatha edulis (vahl) forssk. ex endl. (celestraceae) (khat) on pharmacokinetics of clinically used drugs	17
The impact of COVID-19 infection on cytochrome P450 3A4-mediated drug metabolism and drug interactions	17
Machine learning and deep learning approaches for enhanced prediction of hERG blockade: a comprehensive QSAR modeling study	17
Hormones, microbes, and PrEP drugs in the female genital tract	16
Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis	16

Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter-2 inhibitor, with phentermine in healthy subjects	16
Pharmacology of viable mechanism agnostic respiratory stimulants for the reversal of drug-induced respiratory depression in humans	15
Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease lead to depression?	15
Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications	15
Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids	14
Inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: now and the future	14
Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice	14
Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healt	14
Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients	14
Interactions between grapefruit juice and psychotropic medications: an update of the literature and an original case series	13
Guidance for interactions between antiseizure medications	13
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis	13
An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria	12
Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors	12
Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis	12
CAR-T cell therapies for cancer: what novel technologies are being developed for toxicity data?	12
Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes	12
Toxic metabolites and metabolic soft spots of celastrol based on glutathione metabolic capture and high-resolution mass spectrometry	12
Asparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understanding	11
Overview of preclinical and clinical studies investigating pharmacokinetics and drug–drug interactions of padsevonil	11
Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease	11
Probing the mechanism of reduced in vivo potency of insulin detemir	11
Drug-drug interactions between COVID-19 therapeutics and psychotropic medications	10
Drug-drug interactions between antiseizure medications and antipsychotic medications: a narrative review and expert opinion	10
Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata	10
The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature	9
Studying the right transporter at the right time: an in vitro strategy for assessing drug-drug interaction risk during drug discovery and development	9
Predictive Modelling in pharmacokinetics: from in-silico simulations to personalized medicine	9
Tyrosine kinase inhibitors: the role of pharmacokinetics and pharmacogenetics	9
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine	9
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database	9
Transporters and drug secretion into human breast milk	9
Exploring the level of agreement among different drug-drug interaction checkers: a comparative study on direct oral anticoagulants	9
Pharmacokinetic review of janus kinase inhibitors and its clinical implications for the management of rheumatoid arthritis	9
Drug interactions in people with HIV treated with antivirals for other viral illnesses	9
Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence	8
The role of pharmacogenetics in the treatment of anxiety disorders and the future potential for targeted therapeutics	8
How close are we to personalized mitotane dosing in the treatment of adrenocortical carcinoma? State of the art and future perspectives	8
The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV	8
Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability	8
Development and evaluation of a physiologically based pharmacokinetic model to predict carvedilol-paroxetine metabolic drug–drug interaction in healthy adults and its extrapolation to virtual chronic	8
Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update	8
Individualized dosing algorithms for tacrolimus in kidney transplant recipients: current status and unmet needs	8
The influence of female sex and estrogens on drug pharmacokinetics: what is the evidence?	8
Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease	8
The impact of pregnancy and associated hormones on the pharmacokinetics of Δ 9 -tetrahydrocannabinol	7
How can we optimize the use of methotrexate to treat pediatric patients with inflammatory skin diseases?	7
What is the significance of the impact of antipsychotics on the gut microbiome?	7
The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events	7
A critical review of methotrexate clinical interactions: role of transporters	7

The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1/2 clinical study	7
In silico prediction of drug-induced nephrotoxicity: current progress and pitfalls	7
Ceftazidime dosing in obese patients: is it time for more?	7
Bioactivity descriptors for in vivo toxicity prediction: now and the future	6
Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury	6
Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what’s new?	6
Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia	6
Prescription of statins and pharmacokinetic interactions in Colombian patients	6
Chronic kidney disease and physiologically based pharmacokinetic modeling: a critical review of existing models	6
Advances in the understanding of acetaminophen toxicity mechanisms: a clinical toxicology perspective	6
In NAMs we trust – an innovative paradigm-shift in risk-based chemicals management for globally harmonized protection goals	6
Evaluating the pharmacokinetics of upadacitinib for the treatment of moderate-to-severe Crohn’s disease	6
Risk factors associated with high-dose methotrexate induced toxicities	5
Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia	5
Recent progress in adverse events of carboxylic acid non-steroidal anti-inflammatory drugs (CBA-NSAIDs) and their association with the metabolism: the consequences on mitochondrial dysfunction and oxi	5
Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections	5
Current opinion on the pharmacogenomics of paclitaxel-induced toxicity	5
Evaluating the risk of toxicity and adverse drug interactions involving recreational GHB use and prescribed drugs	5
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer	5
Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer’s	5
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study	5
Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more	5
Dose optimization of β-lactam antibiotics in children: from population pharmacokinetics to individualized therapy	5
Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in vigibase	5
Drug dosing optimization in critically ill children under continuous renal replacement therapy: from basic concepts to the bedside model informed precision dosing	5
Correction	5
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis	5
The influence of pharmacodynamics and pharmacokinetics on the antimigraine efficacy and safety of novel anti-CGRPergic pharmacotherapies: a narrative review	5
Comparison of pharmacokinetic properties of alteplase and tenecteplase. The future of thrombolysis in acute ischemic stroke	4
Clinical pharmacokinetics and pharmacodynamics of oral systemic nonbiologic therapies for psoriasis patients	4
Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties	4
A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition	4
A comprehensive review of the efficacy and safety of ertugliflozin	4
Update on drug-drug interaction at organic cation transporters: mechanisms, clinical impact, and proposal for advancedin vitrotesting	4
Considerations for drug–drug interactions between long-acting antiretrovirals and immunosuppressants for solid organ transplantation	4
Pharmacokinetic considerations surrounding triple therapy for uncontrolled asthma	4
The pharmacokinetic evaluation of omadacycline (Oral Only Dosing Regimen) for the treatment of Community-Acquired Bacterial Pneumonia (CABP)	4
Pharmacokinetics during therapeutic hypothermia in neonates: from pathophysiology to translational knowledge and physiologically-based pharmacokinetic (PBPK) modeling	4
Organotypic-liver slide culture systems to explore the role of extracellular vesicles in pancreatic cancer metastatic behavior and guide new therapeutic approaches	4
Examination of the emerging role of transporters in the assessment of nephrotoxicity	4
Therapeutic drug monitoring of TNFα inhibitors: a spotlight on novel techniques and assays	4
The quest to define cancer-specific systems parameters for personalized dosing in oncology	4
Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir	4
A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects	4
Milvexian, a novel factor XIa inhibitor for stroke prevention: pharmacokinetic and pharmacodynamic evaluation	4
A comprehensive update of the metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation	4
Pharmacogenetic guided drug therapy – how to deal with phenoconversion in polypharmacy	4
Personalization of drug dose thematic issue: introduction article	4
Predicting drug–drug interactions in breast cancer patients treated with CDK4/6 inhibitors and forward planning	4
Managing intoxications with nicotine-containing e-liquids	4
Hepatotoxicity of newer antiseizure medications in children: an overview and disproportionality analysis of VigiBase	4
Deep learning neural network derivation and testing to distinguish acute poisonings	3
An update on the pharmacogenetic considerations when prescribing dopamine receptor agonists for Parkinson’s disease	3
Contribution of aldehyde oxidase to methotrexate-induced hepatotoxicity: in vitro and pharmacoepidemiological approaches	3
Renal and non-renal response of ABC and SLC transporters in chronic kidney disease	3
Beyond animal models: implementing the 3Rs principles and improving pharmacological studies with new model systems	3
Recent advances in cell-based in vitro models for predicting drug permeability across brain, intestinal, and pulmonary barriers	3
Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated	3
Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase	3
The Potential Role of POR*28 and CYP1A2*F Genetic Variations and Lifestyle Factors on Clozapine and N-DesmethylClozapine Plasma Levels in Schizophrenia Patients	3
Physiologically based pharmacokinetic modeling in obesity: applications and challenges	3
Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders	3
Drug interactions in cardiology: focus on statins and their combination with other lipid-lowering drugs	3
Clinical pharmacokinetics of antipsychotics in pediatric populations: a scoping review focusing on dosing regimen	3
Common gastrointestinal drug-drug interactions in geriatrics and the importance of careful planning	3
Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics	3
Biology and therapeutic applications of the proton-coupled folate transporter	3
A repeat-dose toxicity study of human umbilical cord mesenchymal stem cells in NOG mice by intravenous injection	3
Drug-induced liver injury associated with the use of newer antiseizure medications in the elderly: an analysis of data from VigiBase	3
Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overview	3
Evaluating the pharmacokinetic and pharmacodynamic impact of different modes of ticagrelor administration	3
Clinical pharmacokinetics and pharmacodynamics of nicardipine; a systematic review	3
CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia	3
Pharmacogenomics in Asians: Differences and similarities with other human populations	3
Exposure to antibiotics during pregnancy alters offspring outcomes	3
Are we still on the right path(way)?: the altered expression of the pentose phosphate pathway in solid tumors and the potential of its inhibition in combination therapy	3
Pharmacokinetic evaluation of sofosbuvir/velpatasvir for the treatment of Chronic Hepatitis C in pediatrics aged 3 and older	3
A high-throughput liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of p -cresol sulfate, p -cresol	2
Improving on in-silico prediction of oral drug bioavailability	2
Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody–drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach	2

The mysteries of target site concentrations of antibiotics in bone and joint infections: what is known? A narrative review	2
Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout	2
Pharmacokinetic evaluation of efanesoctocog alfa: breakthrough factor VIII therapy for hemophilia A	2
Local anesthetics and erector spinae plane blocks: a spotlight on pharmacokinetic considerations and toxicity risks	2
Drug–drug interactions involving antipsychotics and antihypertensives	2
In-depth mechanistic analysis including high-throughput RNA sequencing in the prediction of functional and structural cardiotoxicants using hiPSC cardiomyocytes	2
Drug absorption from oral formulations in patients with short bowel syndrome: a comprehensive update of the literature	2
Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review	2
Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage	2
Sex-specific UGT expression and function: prevalence, potential mechanisms and significance	2
Enhancing drug-drug Interaction Prediction by Integrating Physiologically-Based Pharmacokinetic Model with Fraction Metabolized by CYP3A4	2
Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: part 2. development of oral dosage formulations	2
Current strategies for predicting side effects from second generation antipsychotics in youth	2
Sex-gender differences in pharmacokinetics	2
Risk factors and prediction for DILI in clinical practice	2
Gut microbiota-drug interactions in cancer pharmacotherapies: implications for efficacy and adverse effects	2
Genetic variation in organic cation transporters and considerations in drug development	2
Pharmacokinetic drug interactions with oral haloperidol in adults: dose correction factors from a combined weighted analysis	2
Individualizing busulfan dose in specific populations and evaluating the risk of pharmacokinetic drug-drug interactions	2
Drug–drug interactions in HIV-infected patients receiving chemotherapy	2
What is the most effective and safest Non-steroidal anti-inflammatory drug for treating osteoarthritis in patients with comorbidities?	2
Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse	2
Pharmacokinetic studies in dialysis-dependent patients: limited data availability	2
Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care – an overview	2
Optimizing co-prescription of clozapine and antiseizure medications: a systematic review and expert recommendations for clinical practice	2
Ceftobiprole medocaril for skin and skin-structure infections	2
JAK1 inhibitors for the treatment of atopic dermatitis: a focus on pharmacokinetic considerations	2
A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens	2
Drug-drug interactions between psychotropic medications and oral contraceptives	2
An Update on the Use of Allometric and Other Scaling Methods to Scale Drug Clearance in Children: Towards Decision Tables	2